Voyager Therapeutics, a new gene therapy company focused on CNS diseases, including Friedreich's Ataxia (FA), is launched

Voyager Therapeutics, a new gene therapy company focused on CNS diseases, including Friedreich's Ataxia (FA), is launched. FARA Press Release, February 12, 2014

Downingtown, PA- February 12, 2014- FARA is pleased to recognize today's launch of Voyager Therapeutics and its commitment to developing gene therapies for central nervous system disorders, including FA. Voyager is backed by leading life sciences investor Third Rock Ventures, and the company has assembled leaders in adeno-associated virus (AAV) gene therapy to develop life-changing treatments with the goal of dramatically improving patients’ lives. See press release from Voyager Therapeutics: http://www.voyagertherapeutics.com/pdfs/Voyager_02.11.14.pdf